Two-Drug attack on blood cancer shows promise in early testing
NCT ID NCT04792502
Summary
This study is testing whether combining two drugs—mosunetuzumab and lenalidomide—works better than current treatments for people newly diagnosed with certain slow-growing lymphomas. The trial will enroll 52 adults who haven't had any previous cancer treatment. Doctors will adjust the treatment plan based on how well patients respond after the first four cycles, adding the second drug if needed for better results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lifespan Cancer Insitute
RECRUITINGProvidence, Rhode Island, 02903, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Rutgers Cancer Institute of New Jersey
RECRUITINGNew Brunswick, New Jersey, 08901, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Yale Cancer Center
NOT_YET_RECRUITINGNew Haven, Connecticut, 06511, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.